Recurrent Islet Cell Carcinoma Completed Phase 1 Trials for Everolimus (DB01590)

IndicationStatusPhase
DBCOND0028802 (Recurrent Islet Cell Carcinoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00655655Everolimus and Vatalanib in Treating Patients With Advanced Solid TumorsTreatment